Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).-Reference-Cited by-同舟云学术

Phase 1 study of dabrafenib in pediatric patients (pts) with relapsed or refractory BRAF V600E high- and low-grade gliomas (HGG, LGG), Langerhans cell histiocytosis (LCH), and other solid tumors (OST).

Published:2015-05-20 Issue:15_suppl Volume:33 Page:10004-10004
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Kieran Mark W.¹,Hargrave Darren R²,Cohen Kenneth J.³,Aerts Isabelle⁴,Dunkel Ira J.⁵,Hummel Trent Ryan⁶,Jimenez Irene⁴,Pearson Andrew DJ⁷,Pratilas Christine A.⁸,Whitlock James⁹,Bouffet Eric⁹,Shen Wei-Ping Violet¹⁰,Broniscer Alberto¹¹,Bertozzi Anne-Isabelle¹²,Sandberg Joan L¹³,Florance Allison M.¹⁴,Suttle Benjamin B.¹⁵,Haney Pat¹⁶,Russo Mark W.¹⁷,Geoerger Birgit¹⁸

Affiliation:

1. Dana-Farber Cancer Inst-PND, Boston, MA

2. Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom

3. Johns Hopkins Univ SOM, Baltimore, MD

4. Institut Curie, Paris, France

5. Memorial Sloan Kettering Cancer Center, New York, NY

6. Cincinnati Children's Hosp Medcl Ctr, Cincinnati, OH

7. Royal Marsden Hospital, Surrey, United Kingdom

8. Johns Hopkins Univ School of Med, Baltimore, MD

9. The Hospital for Sick Children, Toronto, ON, Canada

10. Children's Hosp of Orange Cty, Orange, CA

11. St. Jude Children's Research Hospital, Memphis, TN